Product
Octreotide LAR
1 clinical trial
7 indications
Indication
GEP-NETIndication
Neuroendocrine TumorsIndication
Neuroendocrine tumorIndication
Carcinoid TumorIndication
Pancreatic Neuroendocrine TumorClinical trial
Phase 1b/3 Global, Randomized, Controlled, Open-label Trial Comparing Treatment With RYZ101 to Standard of Care Therapy in Subjects With Inoperable, Advanced, SSTR+, Well-differentiated GEP-NETs That Have Progressed Following Prior 177Lu-SSA TherapyStatus: Active (not recruiting), Estimated PCD: 2025-07-01